Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
The four types of dementia most people don’t know exist 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Drugmaker Merck has partnered with Daiichi Sankyo, under which it will pay $5.5 billion to develop three candidate cancer drugs jointly. This deal could be worth up to $22 billion for Daiichi Sankyo, depending on the success of the therapies.
Shares of Daiichi Sankyo soared by 14.4% in Tokyo, marking their largest gain in over a year. Merck also saw a rise of 1.6% in morning trading.
Ambitious Revenue Target for Daiichi Sankyo's Oncology Business
According to Reuters, Daiichi Sankyo has set a revenue target of at least 900 billion yen ($6 billion) for its oncology business by the fiscal year ending March 31, 2026. This would represent an impressive five-fold increase over three years.
Investopedia noted that the three-drug candidates to be developed with Merck fall into the antibody-drug conjugates (ADC) class, with various stages of clinical development for treating multiple solid cancer tumors. Unlike conventional chemotherapy, ADCs are designed to target cancer cells, minimizing damage to healthy cells specifically.
"One of the changes in the external environment is intensifying competition in ADC development," Daiichi Sankyo CEO Sunao Manabe said, describing the company's decision to seek a partner.
Promising Commercial Revenue Potential
The drug candidates - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan - hold significant worldwide commercial revenue potential for both companies by the mid-2030s, according to Merck and Daiichi Sankyo.
Under the agreement, Merck and Daiichi Sankyo will jointly develop and potentially commercialize the drug candidates globally, except in Japan, where Daiichi Sankyo will retain exclusive rights. Daiichi Sankyo will be responsible for manufacturing and supply.
Merck Gains Access to Daiichi Sankyo's Expertise in the ADC Space
The partnership allows Merck to tap into Daiichi Sankyo's leadership status in the ADC field. Analysts believe this collaboration will strengthen Merck's cancer drug portfolio, particularly as its top-selling Keytruda faces patent expiration at the end of the decade.
In return for the collaboration, Merck will make an upfront payment of $4 billion to Daiichi Sankyo, followed by $1.5 billion in continuation payments over the next two years. Additionally, Merck may pay up to $16.5 billion based on future sales milestones, amounting to $5.5 billion for each product.
Daiichi Sankyo has six ADC candidates in its pipeline, including two jointly developed with AstraZeneca. However, this week's disappointing data abstract on the late-stage trial of datopotamab deruxtecan, developed with AstraZeneca, has impacted analysts' expectations.
Photo: Merck Media
